¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ) 2020³â Á¦72Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ : 2020-10-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ) 2020³â Á¦72Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ : 2020-10-17
±³À°ÀÏÀÚ : 2020-10-17
±³À°Àå¼Ò : ¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ µ¿½Ã °³ÃÖ (¿ÀÇÁ¶óÀÎ: ¼­¿ï µå·¡°ï½ÃƼ È£ÅÚ 2Ãþ ÇѶóȦ ¿Ü)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ) 2020³â Á¦72Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ      
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
´ã´çÀÚ : ¼­´ëÇå 
¿¬¶ôó : 02-3473-0284  
À̸ÞÀÏ : kda@derma.or.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 800¸í  
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 25 ½Ã°£ 25ºÐ  
¼¼ºÎ¼ö°­·á : 500,000¿ø      
ºñ°í ¿ÀÇÁ¶óÀÎ Á¤È¸¿ø 70,000 ÁØȸ¿ø 30,000 / ¿Â¶óÀÎ Á¤È¸¿ø 50,000 ÁØȸ¿ø20,000 ¸¸65¼¼ ÀÌ»ó ¸éÁ¦ ºñȸ¿ø 500,000      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10¿ù 17ÀÏ ÇѶó 1+2 13:15~13:20 Introduction  Chair() 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 13:20~13:35 Future of Dermatologist in 4th Industrial Revolution  ¾È°Ç¿µ(û´ã°í¿î¼¼»ó ´ÚÅÍÁöÇǺΰú) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 14:00~14:25 Biologics  ³ªÁ¤ÀÓ(¼­¿ïÀÇ´ë) 
Åä·Ð 10¿ù 17ÀÏ ÇѶó 1+2 14:25~14:30 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 14:30~14:55 New dermatologic drugs and drug candidates  ¹èÁ¤¹Î(°¡Å縯ÀÇ´ë) 
Åä·Ð 10¿ù 17ÀÏ ÇѶó 1+2 14:55~15:00 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 15:30~15:40 Initial Presentation for Pros  ÇãâÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 15:40~15:50 Initial Presentation for Cons  ±èÀÏȯ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 15:50~15:55 Rebuttal by Pros  ÇãâÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 15:55~16:00 Rebuttal by Cons  ±èÀÏȯ(°í·ÁÀÇ´ë) 
±âŸ 10¿ù 17ÀÏ ¹éµÎ 2 16:00~16:10 Discussion with audience  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 16:10~16:20 Initial Presentation for Pros  ¹Ú°æÈÆ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 16:20~16:30 Initial Presentation for Cons  ÇÑÅ¿µ(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 16:30~16:35 Rebuttal by Pros  ¹Ú°æÈÆ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 16:35~16:40 Rebuttal by Cons  ÇÑÅ¿µ(À»ÁöÀÇ´ë) 
±âŸ 10¿ù 17ÀÏ ¹éµÎ 2 16:40~16:50 Discussion with audience  () 
±âŸ 10¿ù 17ÀÏ ÇѶó 3 17:00~17:05 Introduction  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:05~17:16 Cutaneous lupus erythematosus  °íÁÖ¿¬(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:16~17:27 Chronic urticaria  ¹ÚÀºÁÖ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:27~17:38 Mycosis fungoides  ±èÀ¯Âù(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:38~17:49 Rosacea and sensitive skin  ÀÌÁ¾Èñ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:49~18:00 Chronic hand and foot eczema  À̵¿ÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 14:00~14:15 Pain in skin diseases  ±èÁ¤Àº(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 14:15~14:35 Treatment of postherpetic neuralgia  ±èµÎȯ(¿ï»êÀÇ´ë ¸¶ÃëÅëÁõÀÇÇаú) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 14:35~14:50 How to deal with pain during dermatosurgery  º¯Áö¿ø(ÀÎÇÏÀÇ´ë) 
Åä·Ð 10¿ù 17ÀÏ ¹éµÎ 1 14:50~15:00 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 15:30~15:50 Pemphigus (PV & PF)  ±èÁ¾ÈÆ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 15:50~16:10 Atypical pemphigus (PNP, IgA pemphigus, pemphigus herpetiformis, pemphigus vegetans)  ±è¼öÂù(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 16:10~16:30 Bullous pemphigoid, MMP, LAD, HG  ³ëÁÖ¿µ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 16:30~16:50 Epidermolysis bullosa acquisita, Dermatitis herpetiformis  ÀÌÁö¹ü(Àü³²ÀÇ´ë) 
Åä·Ð 10¿ù 17ÀÏ ¹éµÎ 1 16:50~17:00 Q&A  () 
±âŸ 10¿ù 17ÀÏ ¹éµÎ 1 17:30~17:32 Introduction  Chair() 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 17:32~17:48 Seborrheic dermatitis and mimickers  ±èµ¿Çö(Â÷ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 17:48~18:04 Folliculitis and common diseases masquerading as folliculitis  À¯¹Ú¸°(°æÈñÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 18:04~18:20 Practical use of dermoscopy on scalp diseases  ±è¹®¹ü(ºÎ»êÀÇ´ë) 
Åä·Ð 10¿ù 17ÀÏ ¹éµÎ 1 18:20~18:30 Q&A  () 
±âŸ 10¿ù 17ÀÏ ¹éµÎ 2 17:40~17:43 Introduction  Chair() 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 17:43~17:58 The way to precision medicine for alopecia  Á¶¼ºÁø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 17:58~18:13 A move toward precision medicine in melanoma treatment by next generation sequencing  ÀÌ¿µº¹(°¡Å縯ÀÇ´ë) 
Åä·Ð 10¿ù 17ÀÏ ¹éµÎ 2 18:13~18:20 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 15:30~15:35 Introduction  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 15:35~16:20 Common skin disease in animals  È²Ã¶¿ë(¼­¿ï´ë ¼öÀÇ´ë) 
Åä·Ð 10¿ù 17ÀÏ ÇѶó 1+2 16:20~16:30 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 17:00~17:03 Introduction  Chair() 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 17:03~17:25 What you need to know about ingrown nails (22min)  ¹ÚÇö¼±(¼­¿ïÀÇ´ë) 
Åä·Ð 10¿ù 17ÀÏ ¹éµÎ 1 17:25~17:30 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 16:30~16:55 New approach to acne scar treatment for beginners  ÃÖõÇÊ(´ëÇÑÇǺΰúÀÇ»çȸ Á¤º¸ÀÌ»ç/ÇϴôÀ³¦ÇǺΰú) 
Åä·Ð 10¿ù 17ÀÏ ÇѶó 1+2 16:55~17:00 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 17:00~17:25 My clinical approach to the sensitive skin  ±èÀ¯Á¤(´ëÇÑÇǺΰúÀÇ»çȸ ÇмúÀÌ»ç/±¤¸í»õÇϾáÇǺΰú) 
Åä·Ð 10¿ù 17ÀÏ ÇѶó 1+2 17:25~17:30 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 17:30~17:55 The absorbable thread lifting. Where are we up to now?  ±èâ½Ä(´ëÇÑÇǺΰúÀÇ»çȸ ±³À°ÀÌ»ç/âÇǺΰú) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 17:55~18:00 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 13:35~13:40 Introduction  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 13:40~13:55 Epidemiologic Study for Herpes Zoster  ¹Ú¿µ¹Î(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 13:55~14:00 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:15~09:18 Introduction  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:18~09:33 The roles of aryl hydrocarbon receptor and autophagy in skin immune system and skin barrier function  Á¤º¸¿µ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:33~09:48 Drug screening system development with high-throughput sequencing targeting skin-specific T cells in atopic dermatitis  ¹Úâ¿í(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:48~10:03 Application of Modified ¡°Omics¡± Research platform using Exosomes (Àϸí A.M.O.R.E. ¿¬±¸)  ÇÑÇüÁø(°Ç¾çÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 10:03~10:15 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 09:00~09:15 Overview and introduction of board examination  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 09:15~09:40 Keratinization, barrier development and skin immune system  ±è¹Ì¸®(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 09:40~10:05 Atopic dermatitis, contact dermatitis, seborrheic dermatitis and other eczematous dermatitis  À±Çö¼±(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 10:05~10:10 Break  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 10:10~10:35 Papulosquamous disease  ÃÖÀçÀº(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 10:35~10:55 Bacterial and fungal infection  Á¤ÀÇÇö(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 10:55~11:15 Viral and other infection  ¹Úº´Ã¶(´Ü±¹ÀÇ´ë) 
È޽Ġ10¿ù 17ÀÏ ¹éµÎ 1 11:15~11:20 Break  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 11:20~11:35 Mucosal and adnexal disease  ÀÌ»óÀº(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 11:35~12:00 Dermatopathology  ¹ÚÁöÇý(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 09:00~09:10 Overview & Importance  ±èÀÏȯ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 09:10~09:30 Current Devices – Usages, Pros and Cons  ¼ÛÇØÁØ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 09:30~09:50 Melanocytic skin lesions vs Melanoma  ¹®Á¦È£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 09:50~10:10 NMSC – Basal cell carcinoma  ±è¹®¹ü(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 10:10~10:30 NMSC - Actinic keratosis, Bowen, SCC, etc  ±èÁØ¿µ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 10:30~10:50 Benign skin tumors -SK, DF, Eccrine poroma, Vascular tumors etc  ±èÈñÁÖ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 10:50~11:10 Nail disorders - melanonychia, melanoma  À̵¿À±(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 11:10~11:30 Nevus – Congenital, Aquried, Blue nevus  ÀÌ°©¼®(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 08:00~08:03 Introduction  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 08:03~08:48 How to Increase Quality of Line for Psoriasis Patients?  ±èűÕ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 08:48~09:00 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 11:30~11:33 Introduction  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 11:33~12:18 A common misconception when choosing biologics for psoriatic patients  ±èµ¿Çö(Â÷ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 12:18~12:30 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 14:00~14:03 Introduction  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 14:03~14:48 Completely clear skin that lasts with rapidly visible results: Real World Evidence in Korean patients with moderate to severe psoriasis  ±èº´¼ö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 14:48~15:00 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 16:50~16:53 Introduction  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 16:53~17:13 Updateon dupilumab clinical data in adults and adolescents with moderate-to-severeAD  ¼­¿µÁØ(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 17:13~17:33 Koreanreal-world experience with dupilumab  ÇÑÅ¿µ(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 17:33~17:40 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 14:00~14:05 Overview  chair() 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 14:05~14:20 Curettage  ¿Àº´È£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 14:20~14:35 Cryotherapy  ÀÌ°©¼®(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 14:35~14:50 Intralesional injection  ÃÖÁö¿õ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 14:50~15:00 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 15:30~15:35 Overview  chair() 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 15:35~15:45 Diagnosis of hyperpigmentation and hypopigmentation Dermoscopic pattern identification in hyperpigmentary disorders  Á¤º¸¿µ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 15:45~16:00 Differential diagnosis for hypopigmentary disorders  ÃÖÁ¾¿ø(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 16:00~16:10 Treatment of vitiligo Treatment approaches for vitiligo and maintenance treatment  ½ÅÁ¤Çö(ÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 16:10~16:20 Surgical approaches for vitiligo  ¹èÁ¤¹Î(ÈúÇϿ콺ÇǺΰú) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 16:20~16:30 Treatment of dyspigmentation Underlying mechanism of idiopathic guttate hypomelanosis and its treatment modalities  ¿À»óÈ£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 16:30~16:40 Treatment of refractory melasma: How we do it and what¡¯s new?  ÃÖõÇÊ(ÇϴôÀ³¦ÇǺΰú) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 16:40~16:50 How to handle mottled hypopigmentation laser toning?  ÀÌÇØ¿õ(·çÀ̽ºÇǺΰú) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 16:50~17:00 Q&A  () 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:00~09:05 Overview  chair() 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:05~09:20 Effective treatment for acne and acne scar with EBD  °íÁÖ¿¬(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:20~09:35 Wrinkles and Skin textures: Dermal Rejuvenation using EBD  ±¸º»Ã¶(³ªÀ½ÇǺΰú) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:35~09:50 Simple at a glance but tough inside: How to improve enlarged pores with EBD Aged pores, Widening pores with sebaceous hyperactivity, and Others  À¯È­Á¤(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:50~10:00 Case Discussion and Q&A From Floor  °íÁÖ¿¬±¸º»Ã¶À¯È­Á¤() 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:30~17:35 Overview  ÃÖ±¤¼º(ÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:35~17:50 Topical treatment update  ÀÌ»óÈÆ(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:50~18:05 The update of 5 alpha reductase inhibitors use  À¯¹Ú¸°(°æÈñÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 18:05~18:20 Device and emerging treatment  ÇãâÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 18:20~18:30 Q&A  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ) 2020³â Á¦72Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ : 2020-10-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦ 21ȸ °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç ½ÉÆ÷Áö¾ö : 2020-10-17
´ÙÀ½±Û Çѱ¹ÀÇÇй°¸®ÇÐȸ (¿Â¶óÀÎ) 2020³â ÇϹݱâ ÀÇÇй°¸® ½ÉÈ­±³À°2 : 2020-10-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
298 °æ±â ´ëÇÑôÃßÁ¾¾ç¿¬±¸È¸ Á¦18Â÷ Çмú´ëȸ : 2018-08-18 0 1,018 2018-08-08
297 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ iTHA (Innovation & Technology in Hip Athroplasty) : 2018-08-18 0 1,199 2018-08-08
296 ¼­¿ï ´ëÇÑÈäºÎ¿Ü°úÇÐȸ Heart Valve Disease Symposium 2018 : 2018-08-18 0 604 2018-08-08
295 ¼­¿ï °æÈñ´ëÇб³º´¿ø 2018 Kyung Hee Neurosurgery Symposium (ÀÓ¿µÁø ±³¼ö´Ô Á¤³â±â³ä ½ÉÆ÷Áö¿ò) : 2018-08-18 0 1,538 2018-08-08
294 °æ±â ´ëÇÑ°³¿øÀÇÇùÀÇȸ °­¿øÁöȸ ½ÉÆ÷Áö¿ò : 2018-08-18 0 622 2018-08-08
293 ¼­¿ï ´ëÇÑÈäºÎ¿Ü°úÇÐȸ Heart Valve Disease Symposium 2018 : 2018-08-17 0 1,086 2018-08-08
292 ¼­¿ï °æÈñ´ëÇб³º´¿ø Á¦11ȸ »êºÎÀΰú-¼Ò¾Æû¼Ò³â°ú ¼±»ý´Ôµé°ú ÇÔ²²ÇÏ´Â ¿ù·ÊÁý´ãȸ : 2018-08-17 0 915 2018-08-08
291 °­¿ø °­¿øµµÀÇ»çȸ ÀúÇ÷´çÁõ¿¡ ´ëÇÑ °íÂû : 2018-08-16 0 553 2018-08-08
290 ¼­¿ï ´ëÇѽÅÀåÇÐȸ 2018 Update on CKD-MBD: Phosphorous and Magnesium in health and disease : 2018-09-30 0 1,150 2018-07-28
289 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø °³¿øÀǸ¦ À§ÇÑ ¼Ò¾ÆÁúȯ : 2018-09-29 0 856 2018-07-28
288 ¼­¿ï 2018 Çѱ¹Á¤½ÅºÐ¼®ÇÐȸ Á¤½ÅÄ¡·á Àü¹®°úÁ¤ : ¿¬±Ø¼º ÀΰÝÀå¾Ö, ÀÇÁ¸¼º ÀΰÝÀå¾Ö : 2018-09-29 0 1,235 2018-07-28
287 ¼­¿ï 2018 ´ëÇÑâ»óÇÐȸ ±³À°½ÉÆ÷Áö¾ö : 2018-09-29 0 621 2018-07-28
286 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¾È°ú ±Ý¿ä¼¼¹Ì³ª(CSC treatment update) : 2018-09-28 0 1,103 2018-07-28
285 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø 1) ÇǺΠÇ÷°ü Áúȯ 2) »ö¼Ò ÀÌ»óÁõ : 2018-09-27 0 775 2018-07-28
284 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¾È°ú ±Ý¿ä¼¼¹Ì³ª(Æó¼â°¢ ³ì³»Àå) : 2018-09-21 0 1,427 2018-07-28
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷